A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT ID: NCT05140811
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
126 participants
INTERVENTIONAL
2022-01-05
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT03483948
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
NCT00761722
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
NCT05042531
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04202003
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To evaluate the safety and tolerability of IMM01 combined with Azacitidine in patients with AML and MDS.
* To explore the Maximum Tolerated Dose (MTD) of IMM01 combined with Azacitidine, and determine the phase 2 clinical recommended dose (RP2D) of IMM01 combined with Azacitidine.
Secondary study purpose:
* To evaluate the efficacy of IMM01 combined with Azacitidine in patients with AML and MDS.
* To evaluate the Pharmacokinetics and Pharmacodynamics of IMM01 combined with Azacitidine, in patients with AML and MDS.
Exploratory study purpose:
• To evaluate the immunogenicity of IMM01 combined with Azacitidine in patients with AML and MDS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Relapse/Refractory AML
IMM01 and Azacitidine in Relapse/Refractory AML
Interventions:
Drug: IMM01 Drug: Azacitidine
IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Relapsed or Refractory MDS
IMM01 and Azacitidine in Relapse/Refractory MDS
Interventions:
Drug: IMM01 Drug: Azacitidine
IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Treatment naive AML
IMM01 and Azacitidine in treatment naive AML
Interventions:
Drug: IMM01 Drug: Azacitidine
IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Treatment naive MDS and naive CMML
IMM01 and Azacitidine in treatment naive MDS and naive CMML
Interventions:
Drug: IMM01 Drug: Azacitidine
IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males and females ≥18 years of age
3. The Eastern Oncology Collaboration (ECOG) Status of ≤2
4. Life expectancy of at least 3 months.
5. Women and men of reproductive age must agree and use effective contraception during the study period and for three months after the last administration of IMM01, and women of reproductive age must have negative pregnancy test results within seven days prior to administration.
6. White blood cell count ≤ 20×10⁹/L before the first treatment of the study drug (treatment with hydroxyurea is permitted, but not within 3 days before the first treatment of the study drug).
7. Bone marrow aspiration and bone marrow biopsy were agreed during screening and treatment.
8. For those who have received previous chemotherapy or targeted drug therapy, the interval between the first drug administration should be more than 2 weeks;Prior treatment with chimeric antigen receptor T cells (CAR T cells) should be discontinued for at least 12 weeks after initial dosing(for Cohort 1 and 2).
9. Non-hematological adverse reactions have been restored to grade 1 and below (NCI-CTC AE v5.0, except residual hair loss effect),in patients with previous chemotherapy and targeted drug therapy. Hematologic adverse reactions recovered to investigatory-determined acceptance of study drug administration (for cohort 1 and 2).
10. Appropriate organ functions.
Exclusion Criteria
2. Who has received allogeneic hematopoietic stem cell transplantation and other organ transplants; Autologous hematopoietic stem cell transplantation less than six months.
3. Central nervous system leukemia orcentral nervous system invasion.
4. Developed other malignant tumors within 5 years prior to enrollment.Except:
Cured carcinoma in situ and non-melanoma skin cancer of the cervix; Complete remission of disease at least 2 years prior to initial administration and no need for antineoplastic therapy.
5. Patients with a history of active autoimmune diseases;
6. Major surgery within 4 weeks prior to initial treatment;
7. Subjects requiring systemic corticosteroids (equivalent to \>10 mg prednisone/day) or other immunosuppressive agents within 14 days prior to initial treatment or during the study period;
8. Hypertension (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension or unstable angina that is also not controlled by medication;
9. Patients with a history of arterial or deep vein thrombosis within the 6 months prior to enrollment, or evidence or history of bleeding tendency within the 2 months prior to enrollment, regardless of severity.
10. Severe gastrointestinal diseases;
11. With acute lung disease, pulmonary fibrosis, Severe dyspnea, lung insufficiency or continuous oxygen inhalation.
12. Patients who have been severely infected within 4 weeks prior to initial administration;
13. Active hepatitis B or hepatitis C ; human immunodeficiency virus (HIV) antibody is positive.
14. Live attenuated vaccine should be administered within 4 weeks prior to initial administration.
15. Patients with a history of severe allergy to protein drugs (CTCAE V5.0 grade \> 3); Or the patient is allergic to azacytidine.
16. Participate in clinical trials of other drugs 28 days prior to initial dosing.
17. A history of prior neurological or mental disorders, such as epilepsy, dementia, or alcohol, drug or substance abuse, affects compliance.
18. Other conditions that the investigator considers inappropriate for participation in this clinical trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Hematology & Blood Diseases Hospital, China
OTHER
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing gobroad boren hospital
Beijing, , China
Peking university third hospital
Beijing, , China
Xuanwu Hospital, Capital Medical University
Beijing, , China
Chongqing university cancer hospital
Chongqing, , China
Second Affliated Hospital of Army Medical University
Chongqing, , China
Fujian medical university union hospital
Fuzhou, , China
Ganzhou People's Hospital
Ganzhou, , China
Guangdong provincial people hospital
Guangzhou, , China
Nanfang Hospital, Southern Medical University
Guangzhou, , China
Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University
Guangzhou, , China
The first affiliated hospital zhejiang university school of medicine
Hangzhou, , China
The first affiliated hospital of nanchang University
Nanchang, , China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, , China
Shanghai sixth's hospital
Shanghai, , China
Tongren hospital shanghai jiaotong university school of medicine
Shanghai, , China
Shengjing Hospital Affiliated to China Medical University
Shenyang, , China
The First Hospital of China Medical University
Shenyang, , China
Tianjin Blood Disease Hospital
Tianjin, , China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
The affiliated hospital of Xuzhou medical university
Xuzhou, , China
Henan Cancer Hospital
Zhengzhou, , China
The first affiliated hospital of Zhengzhou University
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMM01-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.